Format

Send to

Choose Destination
Yakugaku Zasshi. 2018;138(3):365-371. doi: 10.1248/yakushi.17-00191-5.

[Drug-Drug Interactions with Consideration of Pharmacogenetics].

[Article in Japanese]

Author information

1
School of Pharmacy, Iwate Medical University.

Abstract

 Elderly patients often suffer from a variety of diseases and therefore may be prescribed several kinds of drugs. Interactions between these drugs may cause problems in some patients. Guidelines for drug interactions were released on July 8, 2014 "Drug Interaction Guideline for Drug Development and Labeling Recommendations (Final Draft)". These guidelines include the theoretical basis for evaluating the mechanisms of drug interaction, the possible extent of drug interactions, and take into consideration special populations (e.g., infants, children, elderly patients, patients with hepatic or renal dysfunction, and subjects with minor deficient alleles for drug metabolizing enzymes and drug transporters). In this symposium article, I discuss this last special population: altered drug metabolism and drug interactions in subjects with minor alleles of genes encoding deficient drug metabolizing enzymes. I further discuss a drug label for eliglustat (Cerdelga) with instructions for patients with ultra-rapid, extensive, intermediate, and poor metabolizer phenotypes that arise from different CYP2D6 gene alleles.

KEYWORDS:

CYP; drug interactions; drug metabolism; eliglustat; flurbiprofen; genetic polymorphism

PMID:
29503430
DOI:
10.1248/yakushi.17-00191-5
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
Loading ...
Support Center